引用次数
引用: 2,596
H-指数: 22
I10-指数 : 43
出版物: 149
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review.
G Curigliano , A Esposito , C Criscitiello , D Trapani
Breast Cancer Research and Treatment
2021
210O Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET)+/-CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)
A Marra , A Gazzo , A Gupta , P Selenica
Annals of Oncology 33 S632 -S632
9
2022
93P An AI-driven computational biomarker from H&E slides recovers cases with low levels of HER2 from immunohistochemically HER2-negative breast cancers
A Marra , M Goldfinger , E Millar , M Hanna
Annals of Oncology 33 S581 -S581
2
2022
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas
P Selenica , A Marra , NJ Choudhury , A Gazzo
Annals of Oncology 33 ( 12) 1284 -1295
29
2022
257P A low fT3/fT4 ratio as a negative prognostic factor in patients with metastatic breast cancer
R Scafetta , F Loupakis , RM Marsicano , A Carnevale Schianca
ESMO Open 9
2024
226P Prevalence and characteristics of HR+/HER2-MBC with ESR1 mutations post-CDK inhibitor therapy
R Scafetta , K Venetis , G Cursano , S Gandini
ESMO Open 9
2024
European Society for Medical Oncology and the Japanese Society of Medical Oncology
T Helleday , RJ van Soest , V Ribrag , C Sarkozy
243P Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer
S Morganti , A Marra , K Venetis , E Sajjadi
Annals of Oncology 33 S648 -S648
2022
227P Peripheral blood lymphocyte counts predict clinical outcomes in patients with hormone receptor-positive HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
C Vernieri , E Zattarin , L Mariani , A Menichetti
Annals of Oncology 33 S641 -S642
2022
2341P Novel therapeutic opportunities in metaplastic breast cancer
F Pareja , A Gazzo , H Dopeso , D Brown
Annals of Oncology 34 S1193 -S1193
2023
308P Regression-based deep-learning predicts breast cancer recurrence risk score from pathology slides
OSM El Nahhas , CML Loeffler , A Marra , Z Carrero
Annals of Oncology 34 S307 -S307
2023
2313P APOBEC mutagenesis and macrophage infiltration in cancer
A Gazzo , A Marra , Y Zhu , A Gupta
Annals of Oncology 34 S1181 -S1181
2023
95P Italian national policy to access molecular tumor boards: Opportunity or restraint for precision oncology?
E Crimini , L Boscolo Bielo , A Marra , M Repetto
ESMO Open 9
2024
225P Platinum-based chemotherapy and PARP Inhibitors for BRCA mutated metastatic breast cancer (LATER-BC): Retrospective multicentre analysis of post-progression treatments
C Valenza , D Trapani , C Sposetti , L Boscolo Bielo
ESMO Open 8 ( 1)
2023
320P Clinical and pathological characteristics of breast cancers switching from early luminal-like to metastatic triple-negative phenotype
M Ivanova , A Marra , S Morganti , K Venetis
Annals of Oncology 34 S312 -S312
2023
90P Effect of age on safety and efficacy of novel cancer drugs investigated in early phase clinical trials
J Uliano , E Nicolo , S Gandini , F Giugliano
ESMO Open 8 ( 1)
2023
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
G Antonarelli , C Corti , P Tarantino , B Taurelli Salimbeni
ESMO Open 8 ( 4) 101608 -101608
6
2023
206P Prognostic role of tumor-infiltrating lymphocytes (TILs) in first-line HER2-positive (HER2+) metastatic breast cancer (BC): A real-world study
B Taurelli Salimbeni , C Pescia , PPM Berton Giachetti , R Scafetta
ESMO Open 9
2024
236P Survival outcomes of patients (pts) with metastatic lobular breast cancer (mLBC) receiving cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy (ET): A retrospective analysis
G Castellano , C Valenza , F Giugliano , A Carnevale Schianca
ESMO Open 9
2024
35P Genomic and clinical landscape of metastatic hormone receptor-positive breast cancers carrying ESR1 alterations
L Boscolo Bielo , E Guerini Rocco , D Trapani , P Zagami
ESMO Open 9
2024